As a crucial step in preventing influenza among the oldest segment of the population, all individuals aged 70 years and above are being offered free influenza prevention with an enhanced vaccine that provides better protection than the standard vaccination.
The offer is part of a broader public health initiative aimed at increasing vaccination rates and reducing the incidence of influenza-related complications, which annually result in hospitalisations and deaths among the country’s elderly population.
"We are pleased to contribute to the Danish vaccination effort, thereby helping to protect a particularly vulnerable part of the population. Older individuals often have underlying health conditions, in combination with the immune response naturally weakens with age – which is why infections like the flu are especially dangerous for them”, says Dr Klaus Gregaard Madsen, Medical Lead, Vaccines CSL Seqirus Denmark.
The enhanced vaccine being offered this season to those 70 years and above is an adjuvanted vaccine,1 marketed under the name FLUAD®.
An adjuvanted flu vaccine contains a substance that enhances the body's immune response, making the vaccine more effective. This is particularly important for individuals with weakened immune systems, such as the elderly, who may not respond optimally to traditional vaccines. By using an enhanced vaccine, particularly vulnerable groups achieve better protection against the flu, thereby reducing the risk of serious complications.3
The Danish Health Authority informs1 that everyone aged 65 and above will receive an invitation to vaccination via e-Boks or a physical letter during September, with information on where and how they can get vaccinated.
The five regions will once again establish regional vaccination centers this year. To ensure easy access to vaccinations, the regions have also partnered with Danske Lægers Vaccinations Service. In the upcoming season, people can be vaccinated at a regional vaccination center or through Danske Lægers Vaccinations Service.
Appointments can be booked at vacciner.dk, where you can also find the addresses of the nearest vaccination locations.
About Seasonal Influenza
Influenza is a common, contagious seasonal respiratory disease that may cause severe illness and life-threatening complications in some people.4 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death. Because transmission of influenza viruses to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others. Seasonal influenza is a vaccine-preventable disease which exerts an annual health burden across Europe of up to 70,000 deaths.5
The Danish Health Authority recommends annual vaccination for:6
- people aged 65 or older
- people with chronic diseases
- people with severe obesity (BMI >35)
- people with other serious diseases or conditions that make influenza or COVID-19 pose a serious health risk, such as individuals with severe mental illness, Down's syndrome, or severe substance abuse
- pregnant women in their 2nd or 3rd trimester
- household members of individuals with congenital or acquired immune deficiency or children at increased risk of severe influenza or COVID-19
Additionally, early retirees are offered free vaccination against influenza.
The Danish Health Authority offers vaccination from October 1, 2024, until December 20, 2024.6
About CSL Seqirus
CSL Seqirus is part of CSL (ASX:CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
For more information about CSL Seqirus, visit CSL.com.
About CSL
CSL (ASX:CSL) (USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/we-are-csl/vita-original-stories and follow us on Twitter.com/CSL.
For more information about CSL, visit www.CSL.com.
MEDIA CONTACT
Em Dekonor
+44 (0)7920500496
Emmanuella.Dekonor@seqirus.com
DNK-FLUD-24-0003
++++
- Centers for Disease Control and Prevention (CDC), Adjuvanted Flu Vaccine: https://www.cdc.gov/flu/prevent/adjuvant.htm [Accessed September 2024]
- Centers for Disease Control and Prevention (CDC). (2021). Key Facts about Influenza. Retrieved from https://www.cdc.gov/flu/about/keyfacts.htm. [Accessed September 2024]
- European Centre for Disease Prevention and Control (ECDC). Factsheet about seasonal influenza ; available online at https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet [Accessed September 2024]
- Sundhedsstyrelsen: https://www.sst.dk/da/Vaccination [Accessed September 2024]
NRD-FLUD-25-0001 June 2025